Home › Compare › PAIOF vs SBUX

PAIOF vs SBUX: Dividend Comparison 2026

PAIOF yields 20000.00% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAIOF wins by $52481917574412746752.00M in total portfolio value
10 years
PAIOF
PAIOF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full PAIOF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — PAIOF vs SBUX

📍 PAIOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPAIOFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PAIOF + SBUX cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PAIOF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAIOF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, PAIOF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAIOF + SBUX for your $10,000?

PAIOF: 50%SBUX: 50%
100% SBUX50/50100% PAIOF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

PAIOF
No analyst data
Altman Z
-10.7
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAIOF buys
0
SBUX buys
0
No recent congressional trades found for PAIOF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPAIOFSBUX
Forward yield20000.00% ✓2.84%
Annual dividend / share$2.00$2.46 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3% ✓
Portfolio after 10y$52481917574412746752.00M ✓$167.0K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00 ✓$71,136.45
Total dividends collected$52448189483771600896.00M ✓$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: PAIOF vs SBUX ($10,000, DRIP)

YearPAIOF PortfolioPAIOF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,121$420.68+$2.00M → PAIOF
2$377,983,225$375,831,775.70$12,548$648.40+$377.97M → PAIOF
3$66,433,479,469$66,029,037,418.28$14,440$1,013.98+$66433.47M → PAIOF
4$10,916,985,471,987$10,845,901,648,955.73$17,068$1,617.30+$10916985.45M → PAIOF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$20,912$2,649.52+$1677384363.75M → PAIOF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$26,875$4,499.29+$240985175079.11M → PAIOF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$36,771$8,014.12+$32373573631143.66M → PAIOF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$54,542$15,197.11+$4066766648320630.00M → PAIOF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$89,602$31,242.49+$477730483406513344.00M → PAIOF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$167,011$71,136.45+$52481917574412746752.00M → PAIOF

PAIOF vs SBUX: Complete Analysis 2026

PAIOF — Stock

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

Full PAIOF Calculator →

SBUX — Consumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this PAIOF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAIOF vs SCHDPAIOF vs JEPIPAIOF vs OPAIOF vs KOPAIOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.